[go: up one dir, main page]

WO2016110173A1 - Nouvel inhibiteur de la neuraminidase du virus de la grippe et utilisations de celui-ci - Google Patents

Nouvel inhibiteur de la neuraminidase du virus de la grippe et utilisations de celui-ci Download PDF

Info

Publication number
WO2016110173A1
WO2016110173A1 PCT/CN2015/097322 CN2015097322W WO2016110173A1 WO 2016110173 A1 WO2016110173 A1 WO 2016110173A1 CN 2015097322 W CN2015097322 W CN 2015097322W WO 2016110173 A1 WO2016110173 A1 WO 2016110173A1
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
icariin
use according
virus
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/097322
Other languages
English (en)
Chinese (zh)
Inventor
庞海
刘爽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilinsheng Diyi Biotechnology Co Ltd
Original Assignee
Jilinsheng Diyi Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilinsheng Diyi Biotechnology Co Ltd filed Critical Jilinsheng Diyi Biotechnology Co Ltd
Publication of WO2016110173A1 publication Critical patent/WO2016110173A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Definitions

  • the present invention relates to a novel inhibitor of influenza virus neuraminidase, which is specifically icariin and a derivative thereof.
  • the present invention also relates to the use of the novel inhibitor for the preparation of a medicament, a food, a health supplement for preventing and/or treating a disease caused by an influenza virus. It belongs to the fields of pharmacy and pharmacology.
  • Influenza virus is an RNA virus that causes influenza in humans, dogs, horses, pigs, mammals, and poultry. Taxonomically, the influenza virus belongs to the Orthomyxoviridae family, which causes acute upper respiratory tract infections and can spread rapidly through the air, causing periodic pandemics around the world. The virus was first known in 1933 by the Englishman Wilson Smith, known as H1N1. H stands for hemagglutinin; N stands for neuraminidase. The numbers represent different types. Human influenza viruses are classified into three types: A (A), B (B), and C (C), which are the pathogens of influenza (flu). Among them, the influenza A virus antigen is susceptible to mutation and has caused a worldwide pandemic many times.
  • influenza virus is spherical, and the newly isolated strain is mostly filamentous, with a diameter between 80 and 120 nanometers, and a filamentous influenza virus with a length of up to 400 nanometers.
  • Influenza virus structure can be divided into envelope, matrix protein and core three parts from the outside.
  • the core of the virus contains the genetic material that stores the virus information and the enzymes necessary to replicate the information.
  • the genetic material of influenza virus is single-stranded negative-strand RNA, abbreviated as ss-RNA. Ss-RNA is combined with nuclear protein (NP) and entangled into ribonucleoprotein body (RNP), which exists in extremely high density. In addition to ribonucleoproteins, there are RNA polymerases responsible for RNA transcription.
  • the RNA of influenza A virus consists of 8 segments.
  • the influenza virus gene consists of eight single-stranded RNA fragments, the NA, HA, NP, M, NS, PB1, PB2, and PA genes, respectively. They encode 10 proteins: Hemagglutinin HA, Neuraminidase NA, Matrix protein 1 M1, Nucleoprotein NP, and RNA-dependent RNA polymerase PB1 , PB2 and PA) Ion channel protein M2 and non-structural proteins NS1 and NS2.
  • the matrix protein constitutes the outer shell skeleton of the virus, and in fact, in addition to the matrix protein (M1), the membrane protein (M2).
  • the M2 protein has an ion (mainly Na+) channel and regulates the pH in the membrane, but in a small amount.
  • the matrix protein binds tightly to the outermost envelope of the virus, protecting the core of the virus and maintaining the spatial structure of the virus.
  • the matrix protein is distributed on the inner wall of the host cell membrane, and the shaped viral nucleocapsid recognizes the site containing the matrix protein on the host cell membrane, binds to form a viral structure, and is budding.
  • the envelope is a layer of phospholipid bilayer membrane wrapped outside the matrix protein. This membrane is derived from the cell membrane of the host. The mature influenza virus sprouts from the host cell, and the host cell membrane is wrapped in the body and then detached from the cell to be infected. Next target.
  • hemagglutinin and neuraminic acid there are two very important glycoproteins in the envelope: hemagglutinin and neuraminic acid. Enzyme. These two types of proteins protrude from the virus in vitro and are about 10 to 40 nanometers in length and are called spikes.
  • an influenza virus surface is distributed with 500 hemagglutinin spikes and 100 neuraminidase spikes.
  • the antigens of hemagglutinin and neuraminidase mutate which is the basis for distinguishing virus strain subtypes.
  • Hemagglutinin is columnar and can bind to receptors on the surface of red blood cells of animals such as humans, birds, and pig guinea pigs to cause blood clotting, so it is called hemagglutinin. After hemagglutinin proteolysis, it is divided into two parts: light chain and heavy chain. The latter can be combined with the sialic acid receptor on the host cell membrane. The former can assist the fusion of the viral envelope and the host cell membrane. Hemagglutinin plays an important role in the introduction of the virus into host cells. Hemagglutinin is immunogenic and anti-hemagglutinin antibodies neutralize influenza viruses.
  • Neuraminidase is a mushroom-like tetrameric glycoprotein with activity in hydrolyzing sialic acid. After the mature influenza virus leaves the host cell in a budding manner, the hemagglutinin on the surface of the virus is kept in contact with the host cell membrane via the sialic acid receptor, and the sialic acid needs to be hydrolyzed by the neuraminidase to cut off the last connection between the virus and the host cell. So that the virus can be released from the host cell smoothly, and then infect the next host cell. Therefore, neuraminidase has also become a target of influenza treatment drugs, and oseltamivir (Duffy) designed for this enzyme is one of the most famous anti-influenza drugs.
  • Duffy oseltamivir
  • H can be divided into 17 subtypes (H1 to H17), and N has 10 subtypes (N1 to N10).
  • H1N1, H2N2, and H3N2 mainly infect humans, and many other subtypes of natural hosts are a variety of birds and animals.
  • H5, H7 and H9 subtype strains are the most harmful to birds.
  • the avian flu virus does not infect animals other than birds and pigs.
  • Hong Kong reported for the first time 18 cases of H5N1 human infection with avian influenza, of which 6 died, causing widespread concern worldwide. Since 1997, there have been several incidents of avian influenza virus infection in the world.
  • the highly pathogenic avian influenza viruses such as H5N1, H7N7, H7N9, and H9N2, once mutated and have human-to-human transmission ability, will lead to human avian influenza epidemic, indicating that the avian influenza virus has great potential for humans. Threat.
  • influenza virus antigens are highly variable, conventional vaccines are not yet effective in preventing influenza outbreaks and epidemics, so anti-influenza drug research is of great significance in influenza treatment.
  • Anti-influenza viruses that have been and are being studied include amantadines, influenza virus neuraminidase inhibitors, influenza virus receptor blockers, and anti-influenza antisense oligonucleotides. Amantadine and rimantadine are commonly used clinical treatment drugs, but they are ineffective against influenza B, easily resistant and neurotoxic; influenza virus neuraminidase inhibitors such as oseltamivir are currently the most effective.
  • influenza virus receptor blockers have obvious antiviral effects
  • anti-influenza virus antisense oligonucleotides have been shown to specifically inhibit viral replication in vitro, and may become a new generation of anti-influenza specific drugs, but They are still in the research stage.
  • Icariin Chinese name is Epimedium
  • English name is Icariin
  • Icariln Ieariline
  • English chemical name is 3-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-7-(beta-D- Glucpyranosy-loxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one, chemical formula: C 33 H 40 O 15 .
  • Natural icariin is found in the genus E. pimedium, mainly distributed in the north temperate zone. There are 23 species of genus Epimedium in the world, and 13 species in China, such as: kinky E.
  • Chinese Patent Application CN1535976A describes in detail a method for extracting and purifying Epimedium from Epimedium. Extracted from the dried stems and leaves of Epimedium, the purified icariin is a pale yellow needle-like crystalline powder. Epimedium and its extract, icariin, have been used in Chinese patent medicines and health care products for many years. Even for thousands of years, no toxic or side effects have been found. It is safe for clinical use in Europe for the treatment of acute and chronic hepatitis. .
  • drugs and health supplements containing icariin and its derivatives can effectively inhibit the activity of influenza virus neuraminidase, thereby achieving the effect of inhibiting the proliferation of influenza virus, and can be used for prevention and/or prevention.
  • the treatment of influenza diseases achieves the object of the present invention.
  • an inhibitor of influenza virus neuraminidase in particular icariin and a derivative thereof. It can be used for the purpose of preventing and/or treating drugs, foods, health products or cosmetics for pathological symptoms or diseases of human or animals caused by influenza viruses.
  • the present invention provides a pharmaceutical composition comprising icariin and a derivative thereof, wherein the pharmaceutical composition contains at least one active ingredient of icariin and a derivative thereof. And the composition may also contain at least one other compound or a herbal ingredient.
  • the present invention also provides a preparation comprising icariin and a derivative thereof or a pharmaceutical composition thereof, and a process for producing the same.
  • a specific object of the present invention is to provide an inhibitor of influenza virus neuraminidase, a composition containing the same, for use in the preparation of a cold medicine or a health supplement for preventing and/or treating influenza virus.
  • the influenza diseases include influenza A, B and C viruses and their respective subtypes and various serotypes thereof, various gene mutants, and serotype variants. That is, H1 to H17, N1 to N10 of influenza A virus, and various gene mutants and serotype variants of M1, M2, PA, PB1, PB2, NS1, NS2; type B and C viruses and their respective Various subtypes and their various serotypes, various gene mutants, serotype variants.
  • icariin an influenza virus neuraminidase inhibitor, icariin and its derivatives, which were screened from natural Chinese herbal medicines without any side effects, to effectively prevent and/or treat diseases caused by influenza virus for the first time. , proved the mechanism of action of the drug. To achieve scientific use of medicine, there is a targeted. It is also the first time that this function of icariin has been discovered, filling the domestic and international gaps in the modernization of Chinese herbal medicine, which is conducive to the rehabilitation of patients.
  • Icariin inhibits influenza virus staining in MDCK cells by fluorescent antibody staining.
  • A MDCK cells infected with influenza virus H5N1, no icariin, all cells are infected with virus
  • B MDCK cells infected with influenza virus H5N1, medium containing 5 ⁇ mol of icariin, only a small number of cells Infected with virus
  • C MDCK cells infected with influenza virus H9N2, no icariin, all cells infected with virus
  • D MDCK cells infected with influenza virus H9N2, medium containing 5 ⁇ mol of icariin, only A small number of cells are infected with the virus.
  • Icariin inhibits influenza virus proliferation in MDCK cells by flow cytometry analysis.
  • A MDCK cells infected with influenza virus H5N1, no icariin, almost all cells are infected with the virus;
  • B MDCK cells infected with influenza virus H5N1, the medium contains 5 ⁇ mol of icariin, only a small amount The cells are infected with the virus;
  • C MDCK cells infected with influenza virus H9N2, no icariin, almost all cells are infected with the virus;
  • D MDCK cells infected with influenza virus H9N2, the medium contains 5 ⁇ mol of icariin Only a small number of cells are infected with the virus.
  • Icariin inhibits the replication of influenza virus in MDCK cells in real time with unlabeled cell function.
  • A MDCK cells infected with influenza virus H5N1
  • the line with triangles is the result of the culture plate wells of virus-infected cells without icariin; the line with dots is the control wells without virus infection; no dots
  • the lines of the triangles and the triangles were plate wells with a gradient of concentration of 1 ⁇ mol, 5 ⁇ mol, 10 ⁇ mol, 20 ⁇ mol, 50 ⁇ mol, 100 ⁇ mol, and 200 ⁇ mol of icariin.
  • the line with triangles is the result of the culture plate wells of virus-infected cells without icariin; the line with dots is the control wells without virus infection; no dots
  • the lines of the triangles and the triangles were plate wells with a gradient of concentration of 1 ⁇ mol, 5 ⁇ mol, 10 ⁇ mol, 20 ⁇ mol, 50 ⁇ mol, 100 ⁇ mol, and 200 ⁇ mol of icariin.
  • FIG. 5 Animal experiments in which icariin inhibits influenza virus.
  • A the average weight gain and decrease of each experimental group after inoculation of H5N1 in mice, that is, the total weight of 10 mice - the total weight of the mice in the first 10 experiments was ⁇ 10, and the solid line represents the infected mice and used 30 mg / The icariin was used to prevent changes in body weight of the experimental group mice (experimental group 2); the dotted line represents the change in body weight of the experimental group mice that did not use icariin after infection with the virus (experimental group 1).
  • the survival rate of the mouse the solid line represents the condition of the mice in the experimental group infected with the infected mice and using 30 mg / icariin (experimental group 2); the dotted line represents the mice infected with the virus without using Epimedium Survival of mice in the experimental group of glycosides (experimental group 1).
  • FIG. 6 Analysis of pathological tissue sections.
  • A normal mouse lung tissue section (experimental group 4).
  • B Normal mice were administered 30 mg/time of icariin in lung tissue sections (experimental group 3), and there were increased immune cells such as macrophages.
  • C lung tissue sections of experimental mice without icariin after infection with mice (experimental group 1), thrombosis in small blood vessels of the lungs, and a small amount of neutrophil degeneration and necrosis in the widened alveolar septum There is a small amount of lymphocyte infiltration around the bronchi.
  • D mice were infected and 30 mg/time of icariin was used to prevent lung tissue sections of experimental mice (experimental group 2), and there was a widening of alveolar septum with a small amount of macrophage infiltration.
  • the icariin is defined by the following formula (I):
  • Xa, Xb, Xc, Xd, Xe, Xf, Xg, Xh, Xi, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 and X 7 are independently an oxygen atom (O) or a sulfur atom (S );
  • Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh and Ri are independently a hydrogen atom (H), a 1-5Ry-substituted alkyl group (C 1 -C 10 ) or (C 1 -C 10 )-O- (C 1 -C 10 ), each alkyl group (C 1 -C 10 ) is substituted with 1-5 Ry, each Ry is Rq, or (C 2 -C 10 )alkyl, (C 3 -C 10 An alkyl group, (C 3 -C 10 )cycloalkylalkyl group, (C 8 -C 14 )bicycloalkylalkyl group, (C 8 -C 14 )tricycloalkylalkyl group, —(C 5 - C 10 ) cycloalkylalkyl, (C 3 -C 10 )cycloalkyl, (C 8 -C 14 )bicycloalkylalkyl, (C 8 -C
  • Xa, Xb, Xb, Xd, Xe, Xf, Xg, Xh, Xi and X 1 , X 2 , X 3 , X 4 , X 5 , X 6 and X 7 are independently oxygen atoms (O And Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently a hydrogen atom (H) , Y 1 , Y 2 and Y 3 are independently CH 3 .
  • Xa, Xb, Xb, Xd, Xe, Xf, Xg, Xh, Xi and X 1 , X 2 , X 3 , X 4 , X 5 , X 6 and X 7 are independently oxygen atoms ( O)
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently a hydrogen atom (H)
  • Y 1 , Y 2 and Y 3 are independently CH 3 .
  • icariin and its derivatives include their individual isomers, racemic or non-racemic mixtures of isomers, oxides, or pharmaceutically acceptable salts thereof And hydrates.
  • the icariin compound can be modified by a group such as amination, carboxylation, aldehyde formation, benzylation or the like to prepare epidemis with different activities and physical and chemical properties.
  • a glycoside compound derivative can be modified by a group such as amination, carboxylation, aldehyde formation, benzylation or the like to prepare epidemis with different activities and physical and chemical properties.
  • the icariin and its icariin derivative used in the present invention may be a natural or chemically synthesized and modified compound having the above formula (I) or (II).
  • the compound can be produced by a known method. Solvents, temperatures, pressures, and other reaction conditions can be readily selected by those skilled in the art. Starting materials are commercially available or can be readily prepared by one skilled in the art by known methods.
  • the natural icariin used in the present invention is extracted and purified from Epimedium plants.
  • the natural icariin plant is extracted and purified from the Epimedium plant of the Berberidaceae family.
  • the Epimedium plants include E. davidii, E. baojingense, E. icoroanum, and E. icoroanum.
  • E. fargesii E. elongatum, E. acuminatum, E. simplicifolium, E. brachyrrhizum, multi-flower Epimedium (E. multiflorum), E. enshiense, E. reticulatum, E. sagittatum, E. latisepalum ), E.chlorandrum, E.platypetalum, E. truncatum, E.
  • one skilled in the art screens to inhibit influenza virus neuraminidase activity by inhibiting influenza virus replication by performing enzymatic kinetic experiments using potential candidate compounds.
  • the ratio of the addition of the influenza virus to the icariin may be 1:0.00001-10000, preferably 1:0.0001-1000; more preferably 1 by weight. 0.001-500; most preferably 1:0.01-100 to achieve complete inhibition of influenza virus neuraminidase, thereby inhibiting replication of influenza virus.
  • the prepared icariin and its derivatives treat or prevent pathological symptoms or diseases caused by influenza virus.
  • influenza virus includes influenza virus A, B and C and their various subtypes, serotypes, genotypes, gene mutant viruses; the pathological symptoms or diseases are caused by various viruses of the above viruses Type one or more diseases caused by influenza syndrome.
  • treating refers to a therapeutic treatment and a preventive or preventive measure, wherein the subject's pathological symptoms or disorders are prevented or slowed down (weakened). If a therapeutic amount of icariin and its derivatives according to the methods described herein is accepted, the subject's symptoms are successfully "treated” and the subject shows that symptoms can be observed and/or determined One or more signs and symptoms are reduced and disappeared. It should also be understood that the various modes of treating or preventing a medical condition described herein are intended to mean "significant", which includes all treatment or prevention and less than all treatment or prevention, wherein certain biologically relevant or medically relevant results are achieved.
  • suitable in vitro assays or in vivo assays are performed to determine the effect of a therapeutic agent based on a particular icariin and its derivatives and whether its administration is suitable for treatment.
  • in vitro assays can be performed on representative cells involved in a subject's condition to determine whether a given therapeutic drug based on icariin and its derivatives has an expectation of the virus type. Effect. If a therapeutic amount of icariin and its derivatives according to the methods described herein is accepted, the subject's symptoms are successfully treated, ie, the subject shows that the above pathological symptoms can be observed and/or determined Or one or more signs and symptoms of the disease are reduced and disappeared. It should also be understood that the various modes of treating or preventing a medical condition described herein are intended to mean "significant", which includes all treatment or prevention and less than all treatment or prevention, wherein certain biologically relevant or medically relevant results are achieved.
  • the subject is administered a prophylactically and/or therapeutically effective amount of a medicament comprising icariin and a derivative thereof.
  • the candidate compounds used in the treatment can be tested in a suitable animal model system including, but not limited to, non-human primates (eg, baboons, orangutans, prior to testing the human subject). Monkeys; pet animals such as cats, dogs, snakes, etc; farm animals of pigs, horses, cows, goats, etc.; any animal of laboratory animals such as rats, mice, monkeys, rabbits, and the like.
  • icariin and a derivative thereof are administered to a subject suffering from or at risk of the above-mentioned pathological symptoms or diseases (a state in which the symptoms are readily available) in an attempt to improve the pathological symptoms Or one or more factors of the disease.
  • the term "effective amount” as used herein refers to an amount sufficient to achieve the desired therapeutic and/or prophylactic effect, for example, to cause prevention or alleviation of symptoms associated with pathological symptoms or diseases.
  • the amount of the composition administered to the subject will depend on the type and severity of the disease as well as the nature of the individual, such as the usual health conditions, age, sex, weight, and tolerance to the drug. The amount will also depend on the severity, severity and type of disease. Those skilled in the art will be able to determine the appropriate dosage based on these and other factors.
  • the composition may also be administered in combination with one or more additional therapeutic compounds.
  • the compounds of the invention can be administered to a subject having one or more signs or pathological symptoms of pathological symptoms.
  • therapeutically effective amount refers to an average level that minimizes the physiological effects of symptoms.
  • the dosage will be capable of preventing or reducing the severity or spread of the condition or indication being treated.
  • the correct dosage will depend on the circumstances, such as the condition being treated, the schedule of administration, whether the compound is administered alone or in combination with another therapeutic agent, the plasma half-life of the compound, and the overall health of the subject.
  • the subject can be administered by oral, topical, inhalation, nasal, rectal, transdermal or injection administration.
  • a daily dosage is prepared containing the compound disclosed herein.
  • the regimen is from about 0.1 mg/kg to about 10000 mg/kg body weight, preferably from about 0.1 mg/kg to about 1000 mg/kg body weight, more preferably from 0.1 mg/kg to about 500 mg/kg, and most preferably from 0.5 mg/kg to About 200 mg/kg body weight. It can be administered from 1 to 6 times a day, preferably 2 or 3 times a day.
  • the spacing may also be irregular, and those skilled in the art recognize that the optimal amount of the compound or its pharmaceutically acceptable salt and the interval between single administrations will depend on the nature and extent of the condition to be treated, the form, route and location of administration.
  • the point and the particular condition of the subject being treated are determined and the most preferred protocol can be determined using conventional techniques. It will also be understood by those skilled in the art that the optimal course of treatment, i.e., the amount of the compound administered daily or a pharmaceutically acceptable salt thereof administered over a given number of days, can be utilized by those skilled in the art using conventional therapeutic test methods. determine. In therapeutic applications, relatively high doses in relatively short time intervals are sometimes required until the course of the disease slows or terminates, and preferably until the subject shows a partial or complete improvement in the disease or pathology symptom. Therefore, the patient can perform a prophylactic administration method to the patient.
  • treating a subject with a therapeutically effective amount of a therapeutic control composition described herein can include a single treatment or a series of treatments.
  • the compounds of the invention may be administered with at least one other active ingredient other compound and/or a Chinese medicinal ingredient.
  • the compounds can be administered simultaneously as a separate formulation or in a unit dosage form, or sequentially.
  • the compound is ribavirin (1), interferon, thymosin alpha , transfer factor, zidovudine (ZDV), didanosine, Lamivudine, stavudine, zalcitabine, abacavir, Ribavirin, (Virazole), nevirapine, diarrhife Delavirdine, efavirenz, saquinavir, ritonavir, nelfinavir, indinavir, amprenavir, Lopinavir, King Kong Amantadine, Rimantadine, Zanamivir, Acyclovir, Valacyclovir, Idoxuridine, Vidarabine , Lamivudine, Famciclovir, Penciclovir, os
  • the plurality of therapeutic agents can be administered in any order or even simultaneously. If at the same time, the plurality of therapeutic agents can be provided in a single, uniform form. Or in multiple forms (for example, as a single tablet or as separate tablets or capsules, several different formulations of pills). One of the therapeutic agents may be provided in a multi-dose form, or Several may be provided as a multi-dose type. If not simultaneously, the time interval between multiple doses may range from greater than 0 weeks to less than about 1 week, less than about 2 weeks, less than about 4 weeks, less than about 2 months, A change in the range of less than about 4 months or even less than about half a year.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit comprising a separate predetermined amount of compound or in combination with other agents, the amount being calculated Sufficient to combine with a pharmaceutically acceptable diluent, carrier or vehicle to produce the desired effect.
  • a pharmaceutical composition containing icariin or a derivative thereof for treating and/or preventing a pathological symptom or disease associated with an improvement of a cold disease caused by an influenza virus is prepared. It is administered to a subject by oral administration, injection, inhalation, or the like. Therefore, the pharmaceutical composition of the present invention can be prepared into various dosage forms.
  • the composition for oral administration can be a capsule, a dropping pill, a gel, a tablet, a powder, a granule, a lozenge, an effervescent tablet, or a syrup.
  • composition for external use may be a smear-type drug, a cream, an external application, an ointment, a topical syrup, a liquid spray, an air spray, or the like.
  • composition for administration by inhalation may be a solution, a dispersion, a dry powder or the like; or a high-purity icariin compound may be extracted from the Chinese herbal medicine Epimedium, and a liposome-encapsulated nano icariin is prepared and prepared. Injectable preparations and sustained release pharmaceutical dosage forms.
  • the proportion of icariin or a derivative thereof is from 0.0% to 99.0%, preferably from 0.0% to 90%, more preferably 10% by weight based on the total weight of the entire preparation. -80%, most preferably 25-70%.
  • the above preparation may be a controlled preparation, including a sustained release tablet or a sustained release capsule.
  • the controlled release tablet comprises a core and a controlled release layer that encapsulates the core.
  • the core contains at least two active ingredients, at least one of which is icariin and a derivative thereof.
  • the core may further comprise at least one other active ingredient of Interferon, Thymosin alpha , Ribavirin, Amantadine, Rimantadine oseltamivir and Zanamivir.
  • the core may also contain at least one other traditional Chinese medicine active ingredient which is one or more combinations of traditional Chinese medicine ingredients such as Radix, Eucalyptus, Forsythia, Honeysuckle, Bupleurum, Andrographis paniculata.
  • the controlled release layer of the controlled release tablet comprises a copolymer of methacrylic acid and ethyl acetate, a copolymer of methacrylic acid and methyl methacrylate, ethyl cellulose, and triethyl citrate.
  • the ratio of the core and the controlled release layer of the package core is 1:0.01-100.
  • a method of preparing a sustained release tablet is provided.
  • the controlled release formulations produced provide pH independent release characteristics in the range of pH 1 to 10.0.
  • the oral preparation is exemplified, and the pharmaceutically acceptable excipients used include, but are not limited to, lubricants and co-solvents such as magnesium stearate, calcium stearate, zinc stearate, stearic acid.
  • the carrier particles may be crystals or spheres of lactose or sucrose; or composite spheres or granules, such as spheres of sugar formed by granulating sucrose with starch as a binder, calcium carbonate spheres or malt paste formed by starch as a binder fine.
  • the carrier particles can also be particles of any other pharmaceutically acceptable excipient such as hydroxypropylcellulose granules, guar gum granules, xanthan gum granules.
  • the carrier can take a wide variety of forms, and all such selections and amounts of adjustments are clearly within the abilities of those skilled in the art.
  • the compound of icariin or a derivative thereof according to the present invention or a composition thereof may comprise a liquid or a water-alcohol which is dissolved in a food or a health care product liquid, such as optionally dissolved in a flavoring. Class solution. It can be incorporated into a swallowable solid excipient, for example in the form of granules, pills, tablets, enteric coated tablets. It can also be placed in a liquid in a food or health supplement, optionally in the swallow capsule. For swallowing, a variety of oral composition embodiments can be employed, and in particular, can be oral composition embodiments of food addenda.
  • enteric coated tablets, colloidal capsules, gels, emulsions, tablets, capsules or solutions are prepared by conventional methods.
  • the active agent according to the invention may be incorporated into a food supplement or any other form of fortified food or health supplement, such as a food or health care product stick, or compressed or uncompressed Among the powders.
  • These powders can be diluted with water, diluted with water in soda, cheese products or soy derivatives, or can be incorporated into food or health care bars.
  • Example 1 Preparation of influenza virus neuraminidase and analysis of its effect on inhibition of influenza virus neuraminidase activity by icariin
  • H5N1 A/chicken/Guangdong/174/04 (H5N1)
  • H9N2 A/chicken/Guangdong/SS/94 (H9N2)
  • the inhibitory effect of the enzyme was also selected from the H9N2 virus strain to prepare a neuraminidase solution, and Triflurane X-100 (Sigma) was added to a concentration of 1% to prepare an influenza virus neuraminidase solution for assay of inhibitor activity.
  • the 98% pure icariin standard (ChromaDex, USA) was dissolved in 30% dimethyl nitrous oxide (Sigma) at a concentration of 10 mmol/L; Methylumbelliferyl-aDN-acetylneuramimic acid (MUNANA, sigma) was formulated into 20 Micromol/L concentration; oseltamivir (Oseltamivir, ChromaDex, USA) was formulated with water to a concentration of 10 mmol/L; 10 times buffer (325 mmol MES (Sigma), 40 mmol CaCl (Sigma), pH 6.5).
  • the enzyme activity assay reaction system was 100 microliters and was carried out in a black 96-well plate.
  • Influenza virus neuraminidase solution was pre-charged with different concentrations of icariin, and then added 3 ⁇ L of reaction buffer, 27 ⁇ L of water, which contained 1 ⁇ mol, 5 ⁇ mol, 50 ⁇ mol, 100 ⁇ mol, 200 ⁇ mol of icariin concentration gradient (final reaction system) concentration).
  • oseltamivir was set as a control experiment according to the above method, and the final reaction system concentration gradient was 1 ⁇ mol, 5 ⁇ mol, 50 ⁇ mol, 100 ⁇ mol, and 200 ⁇ mol.
  • influenza virus neuraminidase solution other components are added at the above concentration, the influenza virus neuraminidase solution is replaced with water
  • no icariin and oseltamivir are added (other ingredients are added according to the above concentration, Replenish the reaction volume with water)
  • add no icariin and oseltami but add 1% DMSO additional of other components at the above concentration, 1% DMSO is the final reaction system concentration).
  • Add the reaction before MUNANA The system is 40 ⁇ L, and each reaction system is shown in Table 1.
  • reaction After reacting at 37 ° C for 1 hour, all the reaction systems were added with 60 ⁇ l of 20 ⁇ mol/L MUNANA, reacted at 37 ° C for 1 hour, and terminated with 0.002 mol/L sodium hydroxide. reaction. Fluorescence intensity was measured using a super-microplate reader (Synergy HT, blo-tek, USA) at 360 excitation light and 460 emission light.
  • icariin Inhibition of influenza virus neuraminidase activity by icariin (Fig. 1) revealed that icariin inhibits influenza virus neuraminidase activity, which is nearly 40 times higher than oseltamivir, suggesting epimedium Glycoside can be used as a lead compound for the prevention and/or treatment of influenza virus diseases, and it is expected to develop a better drug for oseltamivir.
  • this experiment also confirmed that icariin can also inhibit the neuraminidase activity of different subtypes, which can inhibit the activity of N1 (H5N1) and N2 (H9N2) enzymes, suggesting that icariin may inhibit Neuraminidase activity of various subtypes.
  • Example 2 Inhibition of influenza virus by icariin at the in vitro cell level
  • MDCK Mesarby Canine Kidney cells (provided by Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences) were selected as influenza virus proliferating cells, and DMEM (Gibco) was used as the base medium for MDCK cells.
  • MDCK according to the method of Xie et al. (Yi Xie, James A. Schafer. Inhibition of ENaC by intracellular Cl - in an MDCK clone with high ENaC expression. Am J Physiol Renal Physiol.
  • Cell culture 190 mL of DMEM medium was added to 20 mL of fetal bovine serum, 2 mL of green chain double antibody, 7.5% NaHCO 3 to adjust the pH to 7.4. The above components were mixed into MDCK complete medium, 15 passages of cell bottles were added, and the amount of digestive juice was added. It is advisable to cover the cells just before, and gently put them in a 37 ° C incubator for about 10 minutes. When the cells are rounded and do not associate with each other, gently digest the digestive juice, add the culture solution, and repeatedly suck and blow until the cells are The cells were dissociated, and the cells were counted.
  • ⁇ 10 5 /mL cells were seeded in a new 25 mL culture flask, and cultured at 37 ° C in a 5% CO 2 atmosphere.
  • the influenza virus was inoculated into the 9-day-old chicken embryoal allantoic cavity, incubated at 35 ° C for 48-72 h, then the chicken embryo was placed in a refrigerator at 4 ° C overnight, the allantoic fluid was harvested the next day, centrifuged at 3000 rpm for 10 min, and the precipitate was discarded.
  • the serum was subjected to a blood coagulation test, and it was confirmed that the titer was greater than 1:64, and the supernatant was harvested and stored at -80 °C.
  • Influenza virus-infected cells were determined for virus titer: cultured cells were passaged and counted, transferred to a 6-well culture plate, and the cell density per well was adjusted to 1.0 ⁇ 10 5 /mL. Take H5N1 subtype, H9N2 (in order to try to inhibit the effect of icariin on other subtypes of neuraminidase, we also selected H9N2 strain) subtype influenza virus 1mL was added to the A and B cells, The same amount of physiological saline was added to the C well as a negative control. The final volume of each well culture system was adjusted to 5 mL, and A and B cells were incubated for 72 h for a total of 3 groups. Each group was repeated 5 times.
  • Cytopathic effect was observed under a microscope to determine the virus titer.
  • Hatakeyama et al. Shuji Hatakeyama, Yuko Sakai-Tagawa, Maki Kiso, Hideo Goto, Chiharu Kawakami, Keiko Mitamura, Norio Sugaya, Yasuo Suzuki and Yoshihiro Kawaoka.
  • Icariin for Influenza Virus Inhibition Icariin with 30% The dimethyl sigma was dissolved at a concentration of 1 mmol/mL and added to the DMEM cell culture medium. The experimental results of Example 1 were used to determine the concentration of 5 ⁇ mol for the detection of icariin inhibition virus replication assay. Icariin was replaced with PBS as a negative control to inhibit viral replication.
  • Flow cytometry (Beckman Coulter, USA), refer to the method of Liu et al. (Liu H, Zhang GL, Shen L, Zeng Z, Zhou BL, Liu CH, Nie G.
  • a mixture of virus and inhibitor was then added to a 96-well cell electronic assay plate in which MDCK cells had been grown, and placed in a 37 ° C incubator for 190-200 hours.
  • icariin concentration gradients ie, the medium containing 1 ⁇ mol, 5 ⁇ mol, 10 ⁇ mol, 20 ⁇ mol, 50 ⁇ mol, 100 ⁇ mol, 200 ⁇ mol, and a virus-negative control and icariin-free inoculated virus control .
  • Culture and detection were performed using a real-time label-free cell function meter, and data acquisition was performed every 15 minutes.
  • Example 2 Inhibition of influenza virus by icariin at the cellular level in vitro (Example 2), protection of MDCK cells from influenza virus destruction by viral pathogenicity and icariin of MDCK cells, including detection of infection using fluorescent antibodies Influenza-infected cells (Fig. 2), flow cytometry analysis (Fig. 3), and real-time unlabeled cell function analyzer analysis (Fig. 4) are all well demonstrated that icariin can inhibit influenza virus proliferation and protect it. Cells are protected from viruses.
  • Fig. 2 Influenza-infected cells
  • Fig. 3 flow cytometry analysis
  • Fig. 4 real-time unlabeled cell function analyzer analysis
  • neuraminidase virus strain may be a broad-spectrum inhibitor of influenza virus subtypes, serotypes, genotypes, and icariin can be used as a preventive and/or therapeutic agent.
  • the flu virus causes pathological symptoms or diseases of drugs, foods, and health products.
  • mice the Experimental Animal Center of Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, were reproduced.
  • the experimental animal quality license number was Heilongjiang-SYXK 2007-167.
  • mice The animal laboratory air is regularly ventilated and well lit, keeping the room temperature at the implementation room. Five animals were kept per cage, and the puffed feed specially made for mice was fed freely. Before the start of the experiment, observe the animals' feeding, activity and feces for a week. Only healthy mice were selected for the next experiment.
  • the acute toxicity test was used to evaluate the safety of icariin in order to provide a basis for the application of icariin.
  • the maximum tolerance method for acute toxicity test was used.
  • 20 healthy BALB/C mice weighing about 20 g were selected, male and female.
  • the clinically recommended route of administration is oral, and the equity experiment is administered by intragastric administration.
  • Icariin was prepared into a mushy paste with distilled water and administered to mice once a day (about 200 mg of icariin per mouse).
  • the animals were fasted overnight and given free access to water before gavage.
  • the stomach was given a normal diet, the symptoms of poisoning and death were observed and weighed once a week for 2 weeks. Under the same conditions, the same batch of mice were fed with normal food and observed as the control group.
  • the results of the experiment showed that all mice had any symptoms of poisoning, which proved that icariin is a non-toxic substance.
  • Icariin for the prevention of influenza virus infection in animals 6-week-old male BALB/c mice were selected, each group was inoculated with 50 ⁇ L of 102 LD50 H5N1 virus (since H9N2 is pathogenic to mice, so this H9N2) was not selected in the experiment (experimental group 1 and experimental group 2), PBS was used as a negative control (experimental group 4), and a control group (experimental group 3) administered with icariin alone was infected with the virus-infected mouse.
  • four experimental animal groups were set up, each group of 10 mice, each of which was orally administered with 1 mg, which was equivalent to oral administration of icariin 25 mg/kg body weight per day, twice a day for 14 days.
  • mice were weighed once a day, and the changes in body weight and survival rate were observed. Histopathological examination: Selecting the diseased, treatment group, oral administration of icariin and normal mouse lung tissue with 10% neutral-buffered formalin, then correcting and using different concentrations Dehydrated ethanol, soaked in xylene (Sima), embedded in paraffin (Paraffin, Sigma), cut into 3 micron thick slices, placed on glass slides, dewaxed continuously with alcohol, with hematoxylin (Hematoxylin) and Eosin (Sigma) staining were observed under light microscopy.
  • icariin inhibits influenza virus
  • Example 3 An animal experiment in which icariin inhibits influenza virus (Example 3) showed that icariin was able to protect against infection with highly pathogenic avian influenza virus (H5N1) (Fig. 5).
  • H5N1 highly pathogenic avian influenza virus
  • icariin can also promote immune cell infiltration in lung tissue and improve the immune protection of lung tissue (Fig. 6).
  • Icariin can be used in the preparation of icariin and its derivatives for the treatment or prevention of drugs, foods, and health products for pathological symptoms or diseases caused by influenza virus infection.
  • the icariin 0-side composition used in the examples of the present invention may be icariin for purchasing a drug, 200 g of icariin, and pulverized into a fine powder.
  • the component was passed through a 120 mesh sieve, weighed, and the amount of starch and magnesium stearate added in the above table were mixed and poured into a lower hopper.
  • the prepared pellets were filled with a capsule containing amyl saponin by using a hard capsule drug filling machine to fill 200 mg of icariin per two capsules, respectively.
  • Active agent Add amount (g) Icariin 300 Excipient Cassava starch 30 Galactose 20 Microcrystalline cellulose 30
  • Preparation process weigh 200g of icariin, pass 100 mesh sieve, tapioca starch, galactose, microcrystalline cellulose over 80 mesh sieve, mix evenly, add 100g of 6% PVP absolute ethanol solution to prepare granules, 60 °C Dry, 18 mesh sieve dry pellets, 2 g of magnesium stearate was added to the dry pellets.
  • Designing a controlled release formulation for oral administration in accordance with the present invention requires selection and evaluation of the in vitro release profile and timing of the formulation, making it optimal for obtaining the desired in vivo plasma profile, preferably once daily.
  • formulation principles for single unit matrix tablets have been investigated, namely providing formulations with different release profiles.
  • Active agent Add amount (g) Icariin 200 Excipient starch 200 Magnesium stearate 3 Adhesive glucose 2 Maltodextrin 3 Vinyl acetate copolymer 1.5
  • the icariin component or icariin used in the examples of the present invention may be a purchased drug, and 200 g of icariin is weighed and pulverized into a fine powder. The component was passed through a 120 mesh sieve, weighed, and the amount of starch, magnesium stearate, glucose, maltodextrin and vinyl acetate copolymer added in the above table was mixed, passed through a 250 mesh sieve, and then poured into a lower hopper. in.
  • pellets prepared by a and b were filled with a hard capsule drug filling machine according to the coated fine particles to prepare a capsule, that is, a mixed controlled release capsule preparation of the present invention containing 0.5 g of icariin was obtained.
  • Active agent Add amount (g) Icariin 200 Excipient Cassava starch 30 Galactose 20 Microcrystalline cellulose 30
  • Preparation process weigh icariin 200g over 100 mesh sieve, tapioca starch, galactose, microcrystalline cellulose over 80 mesh sieve, mix well, add 100g 6% PVP absolute ethanol solution to granulate, dry at 60 ° C 18 mesh sieved dry granules, and 2 g of magnesium stearate was added to the dry granules.
  • the extended release tablets of the present invention utilize a swellable and partially aggressive polymeric matrix. Based on the hypothetical matrix, the release profile can describe the in vitro release profile of the sample approximately at the square root of time. Obtaining the in vitro release profile that is not affected by the pH value is not affected by the pH value of the gastrointestinal tract when absorbed in the body, and is beneficial to avoid the difference in individual absorption due to the difference in pH of the gastrointestinal tract.
  • the polymer of the present invention constitutes an extended release matrix, and slowly releases icariin as a active ingredient and derivatives thereof and combinations thereof. After administration, after contact with the aqueous liquid, the polymer swells to form a viscous gel layer to regulate drug release.
  • the viscosity of the polymer preferably ranges from 180 to 110,000 mPa.s (apparent viscosity of a 2% aqueous solution at 20 ° C).
  • Example 6 or 7 of the present invention were simultaneously subjected to a release test at different pH values, and a release test curve was drawn based on the release test data. As shown in FIG. 7, the preparation of Example 7 can be seen. The sample has a consistent release profile in each pH medium and its release is virtually unaffected by the pH of the medium.
  • icariin can inhibit the activity of influenza virus neuraminidase, thereby inhibiting the replication of influenza virus, and can be used for the prevention and treatment of various diseases caused by influenza virus infection, food, health care products. Development.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouvel inhibiteur de la neuraminidase du virus de la grippe et ses utilisations dans la préparation de médicaments, d'aliments, et de produits de santé pour la prévention et/ou le traitement de maladies humaines ou animales provoquées par les virus de la grippe. L'inhibiteur de neuraminidase est l'icariine et des dérivés de l'icariine.
PCT/CN2015/097322 2015-01-08 2015-12-15 Nouvel inhibiteur de la neuraminidase du virus de la grippe et utilisations de celui-ci Ceased WO2016110173A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510012661.0 2015-01-08
CN201510012661 2015-01-08

Publications (1)

Publication Number Publication Date
WO2016110173A1 true WO2016110173A1 (fr) 2016-07-14

Family

ID=53903476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/097322 Ceased WO2016110173A1 (fr) 2015-01-08 2015-12-15 Nouvel inhibiteur de la neuraminidase du virus de la grippe et utilisations de celui-ci

Country Status (2)

Country Link
CN (1) CN104857007A (fr)
WO (1) WO2016110173A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112022810A (zh) * 2019-06-03 2020-12-04 鲁南制药集团股份有限公司 一种淫羊藿苷元药物组合物及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105727269B (zh) * 2016-03-22 2018-10-02 中国药科大学 神经氨酸酶及其抑制剂在心肌缺血及心肌梗死中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732925A (zh) * 2005-08-02 2006-02-15 天津药物研究院 一种洛伐他汀缓释微丸及其制备方法
CN1969870A (zh) * 2005-11-24 2007-05-30 北京奇源益德药物研究所 抗病毒复方制剂及其制备方法、质控方法和应用
CN103621567A (zh) * 2013-11-19 2014-03-12 青岛茂丰有机蔬菜有限公司 一种防治流胶病菌的药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100404049C (zh) * 2004-12-31 2008-07-23 中国医学科学院药用植物研究所 一种防治禽流感的药物及其制备方法
CN103083670A (zh) * 2012-10-26 2013-05-08 通化新海生物产业有限公司 一种组织蛋白酶k的抑制剂的用途
CN103265591B (zh) * 2013-05-24 2016-04-20 四川大学 淫羊藿苷衍生物及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732925A (zh) * 2005-08-02 2006-02-15 天津药物研究院 一种洛伐他汀缓释微丸及其制备方法
CN1969870A (zh) * 2005-11-24 2007-05-30 北京奇源益德药物研究所 抗病毒复方制剂及其制备方法、质控方法和应用
CN103621567A (zh) * 2013-11-19 2014-03-12 青岛茂丰有机蔬菜有限公司 一种防治流胶病菌的药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIE, JUANPING ET AL.: "Advances in Studies on Chemical Constituents and Pharmaceuticals in Species of Epimedium", STRAIT PHARMACEUTICAL JOURNAL, vol. 18, no. 5, 31 May 2006 (2006-05-31), pages 19 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112022810A (zh) * 2019-06-03 2020-12-04 鲁南制药集团股份有限公司 一种淫羊藿苷元药物组合物及其制备方法
CN112022810B (zh) * 2019-06-03 2022-05-24 鲁南制药集团股份有限公司 一种淫羊藿苷元药物组合物及其制备方法

Also Published As

Publication number Publication date
CN104857007A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
CN102264222B (zh) 抗病毒补剂
Chakraborty et al. Fighting the flu: a brief review on anti-influenza agents
WO2021179950A1 (fr) Utilisation d'une composition pharmaceutique dans la préparation d'un médicament antiviral
TWI453026B (zh) 魚針草萃取物及其純化物抗流感病毒之用途
Liang et al. Advances research in porcine enteric coronavirus therapies and antiviral drugs
CN101906122B (zh) 野漆树苷的提取方法及其制备药物用途
CN101891785B (zh) 金丝桃苷的提取方法及其制备药物的用途
WO2016110173A1 (fr) Nouvel inhibiteur de la neuraminidase du virus de la grippe et utilisations de celui-ci
KR101160743B1 (ko) 녹차를 유효성분으로 함유하는 조류 인플루엔자에 대한 항바이러스제
CA2465062C (fr) Agent preventif et/ou therapeutique contre les infections virales
CN102068452B (zh) 一种具有抗病毒作用的药物组合物
CN107663158B (zh) 奥司他韦羧酸盐酸盐及其雾化剂的制备方法
CN102836168B (zh) 吲哚-3-乙腈-6-O-β-D-吡喃葡萄糖苷在制药中的应用
CN102633850A (zh) 野漆树苷的提取方法及其制备药物用途
CN101884651A (zh) 山香圆叶水提取物及其制备方法和用途
CN106943416B (zh) 药物组合物及其在制备治疗肺炎或/和增强上呼吸道感染中自然杀伤细胞活性药物中的应用
JP5372547B2 (ja) 免疫グロブリンａ産生促進剤
CA3224519A1 (fr) Compositions et methodes de traitement et de prevention d'infections virales
CN102166276B (zh) 一种防治甲型流感的中药组合物及其制备方法和用途
CN102772398A (zh) 二氢杨梅素在制备防治流感药物中的应用
CN106265684A (zh) 乙酰羽扇豆醇酯的应用
CN105434631A (zh) 花椒精油在制备用于预防和/或治疗病毒性流感的药物或保健品中的应用
CN114377009A (zh) Sb216763在制备抗流感病毒药物中的应用
CN101879197B (zh) 山香圆叶乙醇回流提取物及其制备方法和用途
CN102526086A (zh) 女贞苷的提取方法及其制备药物用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15876673

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 01-12-17)

122 Ep: pct application non-entry in european phase

Ref document number: 15876673

Country of ref document: EP

Kind code of ref document: A1